The company's principal activities are to conduct research and development of tissue engineered skin regeneration product, for use in the treatment of chronic and acute wounds. The group has developed a proprietary and patented technology known as orcel, which is used to stimulate the repair and regeneration of human skin. Orcel is a two layered tissue engineered dressing that consists of human derived skin cells, both dermal and epidermal, supported within a porous collagen matrix. The composite matrix is seeded with keratinocytes for epidermal growth and fibroblasts for dermal growth. The company also conducts a pivotal clinical trial for the use of orcel in its cryopreserved form for the treatment of venous leg stasis and diabetic foot ulcers.
